Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Masaki Ogino

Eiji Kimura

Tatsuki Koike

Takeshi Wakabayashi

Masami Yamada

Yuhei Miyanohana

Jinichi Yonemori

Kenichiro Shimokawa

Tomoko Ohashi

Hideo Suzuki

Shinkichi Suzuki

Norihito Tokunaga

Toshihiro Imaeda

Yuichi Kajita

Tomohiro Okawa

Masaki Daini

Masataka Murakami

Satoshi Mikami

Kohei Takeuchi

Ikuo Fujimori

Makoto Fushimi

Shogo Marui

Tomohiro Ohashi

Masaki Seto

Takahiro Sugimoto

Hiroyuki Tawada

Haruhi Ando

Kazuaki Takami

Yuya Oguro

Tomohiro Kaku

Shigemitsu Matsumoto

Hironobu Maezaki

Yasutomi Asano

Ayumu Sato

Mitsuhiro Ito

Taku Kamei

Shinobu Sasaki

Yasuhisa Kohara

Steve Swann

Yasuhiro Tsukimi

Yasushi Hattori

Minoru Nakamura

Hiroki Sakamoto

Takeshi Yamasaki

Tsuneo Oda

Makoto Kamata

Takuto Kojima

Yasutaka Hoashi

Yoshiteru Ito

Keisuke Imamura

Nobuyuki Takakura

Takahiro Matsumoto

Tohru Miyazaki

Shizuo Kasai

Koichiro Fukuda

Yoshihiro Banno

Tatsuhiko Fujimoto

Zen-ichi Terashita

Tohru Yamashita

Masatoshi Hazama

Yuta Tanaka

Hideki Hirose

Asato Kina

Kentaro Rikimaru

Satoru Oi

Hiromichi Sugimoto

Ryo Mizojiri

Masahira Nakamura

Sachie Morimoto

Tomoko Ashizawa

Taihei Yamane

Kohei Notoya

Ryosuke Arai

Koji Ikedou

Kei Masuda

Yuki Hanya

Takashi Nakahata

Osamu Yabe

Koji Takeuchi

Norio Oyabu

Kouji Fuji

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound and application thereof

The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Substituted pyrrolidine compound and use thereof

Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

Aromatic ring compound

The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification. 

Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Nitrogen-containing heterocyclic compound

Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification. 

Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

The present invention relates to an alkaline earth metal salt or an organic amine salt of a compound represented by the formula [I]: wherein Rand Rare each a hydrogen atom, a halogen atom, or an optionally substituted linear hydrocarbon group; ring A is an optionally further substituted benzene ring; B is an optionally substituted benzene ring; R is a carboxyl group or a linear hydrocarbon group substituted with a carboxyl group and the like. 

Coumarin derivative and use thereof

The present invention provides a compound of the formula: wherein ring A is an optionally substituted 5 to 10-membered aromatic ring; Rand Rare the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond and the like; and L is a divalent hydrocarbon group, and a salt thereof, except 3-(aminomethyl)-2,6,7-trimethyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-6-chloro-2-methyl-4-phenyl-1(2H)-isoquinolinone and 3-(aminomethyl)-2-isopropyl-4-phenyl-1(2H)-isoquinolinone. The compound shows a superior peptidase-inhibitory activity and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Fused heterocyclic compounds

The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula:in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is &#x2014;NR&#x2014; (in which Ris a hydrocarbon or the like); D is a Calkylene group or the like; E is &#x2014;NH&#x2014; or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and Rmay be taken together with a constituent atom of the ring B to form a ring.

Lipid-rich plaque inhibitors

Growing community of inventors

Kanagawa, Japan

Masaki Ogino